The American Society for Experimental NeuroTherapeutics (ASENT) was established in 1996 to facilitate the development of therapies for nervous system disorders by providing a forum for communication among individuals from academia, government, industry, and patient support groups. ASENT has sponsored five annual meetings, focused on providing timely detailed updates in the neurotherapeutics field. The success of these meetings underscored the need for a journal that would provide critical and comprehensive reviews. NeuroRx ® , the official journal of ASENT, was established to serve this purpose. An outstanding Editorial Board was selected, representing the diverse constituencies of the Society. Published quarterly, each issue of NeuroRx ® is devoted to reviews of a single topic relating to neurotherapeutics and is intended to serve as a reference work in that area. Each topic is organized by one or more Guest Editors, who have expertise in the review area. NeuroRx ® will be published both in print and online, and we are particularly fortunate to have secured the services of two premier publishers: Cadmus Professional Communications for print and HighWire Press for online publication.
The Editorial Board has identified areas of particular importance and timeliness. NeuroRx ® is owned by ASENT, which has assumed financial responsibility for the Journal. Both the Society and the Journal leadership recognize the importance of avoiding conflicts of interest (real or perceived), particularly for a journal dedicated to critical reviews and partially sponsored (through the Society) by industry. A statement on Conflict of Interest, covering both the Journal and the Society, appears in this issue. In addition to requiring full disclosure of potential financial interests or consulting relationships, ASENT has established a Publications Oversight Committee, separate from the Editorial Board, to oversee the Journal and address any perceived and potential conflicts of interest. Thus, the Editorial Board will exclusively be involved in determining content and quality, whereas the Publications Oversight Committee will serve to separate the Editorial Board from interactions with sponsors and from the business considerations of the Journal.
We are indebted to those who have agreed to serve on the Editorial Board and Publications Oversight Committee. These individuals are listed in the journal, as well as on the websites for NeuroRx ® and ASENT. It is a privilege to work with these exceptional individuals and with Dr. Patricia A. Grady, our Associate Editor.
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